DOCSLIB.ORG

ANNUAL REPORT 2018-19 2 Notice

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2018-19 2 Notice CONTENTS Corporate Information ............................................................................................................ 02 Notice .................................................................................................................................... 03 Directors’ Report .................................................................................................................... 14 Annexures to Directors’ Report .............................................................................................. 25 Management Discussion and Analysis .................................................................................. 53 Business Responsibility Report ............................................................................................. 69 Report on Corporate Governance ......................................................................................... 80 Standalone Financial Statements .......................................................................................... 99 Consolidated Financial Statements ....................................................................................... 154 Financial Highlights - 5 years ................................................................................................. 212 CORPORATE INFORMATION BOARD OF DIRECTORS STATUTORY AUDITORS 1. Shri Sudhir Mehta B S R & Co. LLP Chairman Emeritus Chartered Accountants 2. Shri Samir Mehta Executive Chairman REGISTERED OFFICE 3. Shri Shailesh Haribhakti Torrent House, 4. Shri Haigreve Khaitan Off Ashram Road, 5. Ms. Ameera Shah Ahmedabad - 380 009, 6. Ms. Nayantara Bali Gujarat, India 7. Dr. Chaitanya Dutt Phone: + 91 79 26599000 Director (Research and Development) Fax: + 91 79 26582100 AUDIT COMMITTEE CORPORATE IDENTITY NUMBER 1. Shri Shailesh Haribhakti L24230GJ1972PLC002126 Chairman WEBSITE 2. Shri Haigreve Khaitan www.torrentpharma.com 3. Ms. Ameera Shah 4. Ms. Nayantara Bali INVESTOR SERVICES EMAIL ID [email protected] SECURITIES TRANSFER AND STAKEHOLDERS RELATIONSHIP COMMITTEE REGISTRAR AND SHARE TRANSFER AGENT 1. Shri Haigreve Khaitan Karvy Fintech Private Limited Chairman Unit: Torrent Pharmaceuticals Limited 2. Shri Shailesh Haribhakti Karvy Selenium Tower-B, 3. Ms. Ameera Shah Plot No. 31 & 32, Financial District, Gachibowli, Hyderabad – 500 032 NOMINATION AND REMUNERATION COMMITTEE Phone: + 91 40 67162222 1. Shri Shailesh Haribhakti Fax: + 91 40 23001153 Chairman Email Id: [email protected] 2. Shri Samir Mehta 3. Shri Haigreve Khaitan CORPORATE SOCIAL RESPONSIBILITY COMMITTEE 1. Ms. Ameera Shah Chairperson 2. Ms. Nayantara Bali 3. Dr. Chaitanya Dutt RISK MANAGEMENT COMMITTEE 1. Shri Shailesh Haribhakti 2. Shri Haigreve Khaitan 3. Shri Sudhir Menon CHIEF FINANCIAL OFFICER Shri Sudhir Menon VP (LEGAL) & COMPANY SECRETARY Shri Mahesh Agrawal ANNUAL REPORT 2018-19 2 NOTICE NOTICE IS HEREBY GIVEN THAT THE FORTY SIXTH ANNUAL GENERAL MEETING OF THE MEMBERS OF TORRENT PHARMACEUTICALS LIMITED will be held on Tuesday, 23rd July, 2019 at 09:30 AM at J. B. Auditorium, Torrent AMA Centre, Ground Floor, Ahmedabad Management Association, Vastrapur, Ahmedabad – 380 015, Gujarat, India, to transact the following business: ORDINARY BUSINESS 1. To receive, consider and adopt the Standalone and Consolidated Financial Statements as at 31st March, 2019 including the Audited Balance Sheet as at 31st March, 2019, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon. 2. To confirm the payment of interim dividend on equity shares already paid during the financial year ended st31 March, 2019 and to declare final dividend on equity shares for the said financial year. The Board of Directors at its meeting held on 30th January, 2019 had declared the interim dividend of ` 13.00 per equity share of fully paid up face value of ` 5.00 each and in its meeting held on 20th May, 2019 recommended final dividend of ` 4.00 per equity share of fully paid up face value of ` 5.00 each for the financial year ended 31st March, 2019. 3. To appoint a Director in place of Shri Samir Mehta (holding DIN 00061903), Director, who retires by rotation, and being eligible, offers himself for re-appointment. SPECIAL BUSINESS 4. To consider and if thought fit, to pass the following resolution as an Ordinary Resolution: RATIFICATION OF REMUNERATION OF COST AUDITORS OF THE COMPANY FOR THE YEAR 2019-20 “ RESOLVED THAT pursuant to provisions of Section 148(3) of the Companies Act, 2013 read with Companies (Cost Records and Audit) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force) (“the Act”) and the approval by the Board of Directors at their meeting dated 20th May, 2019, the consent of the Company be and is hereby accorded for ratification of the below remuneration to M/s. Kirit Mehta & Co., Cost Accountants as the Cost Auditors of the Company for the financial year 2019-20: ` 8,00,000/- plus out of pocket expenses & GST as applicable to conduct the audit of the cost accounting records for all the manufacturing facilities of the Company.” 5. To consider and if thought fit, to pass the following resolution as a Special Resolution: RE-APPOINTMENT OF SHRI SAMIR MEHTA AS EXECUTIVE CHAIRMAN AND FIXATION OF REMUNERATION “ RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 and Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the rules made thereunder and Regulation 17(1B) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and subject to the provisions of Section 152(6) of the Companies Act, 2013 and any other applicable laws (including any statutory modification(s) or re-enactment thereof, for the time being in force) and any other approval as may be required, the consent of the Company be and is hereby accorded for re-appointment of Shri Samir Mehta (holding DIN 00061903) as Executive Chairman of the Company with effect from 30th July, 2019 till 31st March, 2020 on the following terms and conditions: 1. COMMISSION : At a rate such that the total remuneration does not exceed percentage limit of net profits of the Company as specified in the Companies Act, 2013, calculated in accordance with Section 198, subject to the overall ceiling prescribed under Section 197 read with Section I of Part II of Schedule V of the Companies Act, 2013 (including any statutory modification(s) or re-enactment thereof, for the time being in force). 3 2. PERQUISITES : shall be allowed in addition as under: A. (i) The Company shall reimburse annual fees for two clubs. (ii) The Company shall pay the premium on personal accident insurance policy as per the Company rules. (iii) The Company shall pay the premium on medical insurance for self and family as per the Company rules. B. (i) The Company shall provide a car with driver for official and personal use. (ii) The Company shall provide telephones at his residence, the cost of which will be borne by the Company. 3. OTHER TERMS : (i) Such appointment shall not be considered as a break in his service as managerial personnel of the Company. (ii) The total remuneration for any year shall not exceed percentage limit of net profits of the Company as specified in the Companies Act, 2013, calculated in accordance with Section 198, subject to the overall ceiling prescribed under Section 197 read with Section I of Part II of Schedule V of the Companies Act, 2013 as existing or modified or re-enacted. (iii) He shall not be entitled to receive sitting fees for attending meetings of the Board of Directors or a committee thereof. " “RESOLVED FURTHER THAT Shri Samir Mehta shall exercise substantial powers of management subject to superintendence, control and direction of the Board of Directors of the Company.” “ RESOLVED FURTHER THAT in the event of loss or inadequacy of profit in any financial year, the Company shall pay Shri Samir Mehta, in respect of such financial year, remuneration by way of salary, allowances, perquisites and other benefits as the Board of Directors may deem fit, subject to the limits prescribed in Section II of Part II of Schedule V of the Companies Act, 2013 (including any statutory modification(s) or re-enactment thereof, for the time being in force).” “ RESOLVED FURTHER THAT the Board of Directors or any Committee thereof specifically authorized for this purpose be and is hereby authorised to decide the amount of Commission to be paid to Shri Samir Mehta and the periodicity of such payment, subject to the overall limit as specified above, notwithstanding the limits stated in the Regulation 17(6)(e) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof, for the time being in force).” 6. To consider and if thought fit, to pass the following resolution as a Special Resolution: PAYMENT OF COMMISSION TO SHRI SUDHIR MEHTA, CHAIRMAN EMERITUS FOR THE YEAR 2018-19 “ RESOLVED THAT pursuant to Regulation 17(6)(ca) and other applicable provisions, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof, for the time being in force) and other applicable provisions, if any, of the Companies Act, 2013 and pursuant to the approval of the shareholders of the Company at the 42nd Annual General Meeting of the Company, the consent of the Company be and is hereby accorded for payment of Commission
Load more

Recommended publications
  • February 20, 2021 To, To, Corporate Relationship
    February 20, 2021 To, To, Corporate Relationship Department Listing Department BSE Limited, National Stock Exchange of India Limited 14th Floor, P. J. Towers, "Exchange Plaza", C-1, Block G, Dalal Street, Fort, Bandra- Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400 051 SCRIP CODE: 532779 SCRIP SYMBOL: TORNTPOWER Dear Sirs, Sub.: Torrent Power emerges as the highest Bidder for 51% privatization of Power Distribution Company in the UT of Dadra & Nagar Haveli and Daman & Diu Ref: Media release - Regulation 30 read with Schedule Ill to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 We enclose herewith a copy of Media Release being issued by the Company that Torrent Power emerges as the highest Bidder for 51% privatization of Power Distribution Company in the UT of Dadra & Nagar Haveli and Daman & Diu for your records. Thanking you, Yours faithfully, For Torrent Power Limited Rahul Shah Company Secretary TORRENT POWER LIMITED Email: [email protected] CIN: L31200GJ2004PLC044068 Regd. Office: ''Samanvay'', 600, Tapovan, Ambawadi, Ahmedabad 380015, Gujarat, India Phone: 079‐26628300 www.torrentpower.com MEDIA RELEASE Torrent Power emerges as the highest Bidder for 51% privatization of Power Distribution Company in the UT of Dadra & Nagar Haveli and Daman & Diu Revenue Approx ₹ 4,500 Crs p.a. Key statistics Annual Sales & number of consumers for DISCOM of DNH & DD 9,000 Million Units p.a. and ~1.5 lakh consumers Geographical Area 603 Sq. kms February 20, 2021: Torrent Power Limited (the “Company”) today emerged as the highest Bidder for the sale of 51% stake in the Power Distribution Company in the UT of Dadra & Nagar Haveli and Daman & Diu.
    [Show full text]
  • Daiichi Sankyo Move Could Spark Copycats
    June 12, 2008 Daiichi Sankyo move could spark copycats Lisa Urquhart Daiichi Sankyo’s surprise move yesterday on Ranbaxy sparked not only a flurry of news about the $4.1bn deal, but has also got many in the market wondering who else might be on the shopping list of other big pharma companies looking to snap up an Indian generics firm. Those excited by the acquisition are pointing to the attractions of these companies, which include the increasing moves by governments to use generics to reduce healthcare costs, and in the case of Indian generic companies, their access to the fast growing, developing markets that big pharma has already expressed an interest in. With Ranbaxy now out of the picture, according to the EvaluatePharma’s Peer Group Analyzer Glenmark would be one of the most attractive in terms of future growth. The company may not be in the top three of the biggest Indian generics, but it is forecast to report an impressive 38% compound annual growth in unbranded generic sales in the five years to 2012. WW Unbranded Generic Sales WW annual sales ($m) CAGR (07-12) Market Rank 2007 2012 2007 2012 Glenmark Pharmaceuticals 244 1,211 38% 30 16 Wockhardt 357 764 16% 25 20 Lupin 303 647 16% 27 26 Aurobindo Pharma 165 334 15% 31 31 Matrix Laboratories 131 265 15% 34 35 Cipla 872 1,656 14% 14 11 Ranbaxy Laboratories 1,496 2,827 14% 9 6 Torrent Pharmaceuticals 300 543 13% 28 29 Piramal Healthcare 418 756 13% 20 21 Zydus Cadila 395 697 12% 22 24 Sun Pharmaceutical Industries 775 1,332 11% 15 15 Dr.
    [Show full text]
  • Annual Return
    FORM NO. MGT-7 Annual Return [Pursuant to sub-Section(1) of section 92 of the Companies Act, 2013 and sub-rule (1) of (other than OPCs and Small rule 11of the Companies (Management and Companies) Administration) Rules, 2014] Form language English Hindi Refer the instruction kit for filing the form. I. REGISTRATION AND OTHER DETAILS (i) * Corporate Identification Number (CIN) of the company Pre-fill Global Location Number (GLN) of the company * Permanent Account Number (PAN) of the company (ii) (a) Name of the company (b) Registered office address (c) *e-mail ID of the company (d) *Telephone number with STD code (e) Website (iii) Date of Incorporation (iv) Type of the Company Category of the Company Sub-category of the Company (v) Whether company is having share capital Yes No (vi) *Whether shares listed on recognized Stock Exchange(s) Yes No Page 1 of 17 (a) Details of stock exchanges where shares are listed S. No. Stock Exchange Name Code 1 2 (b) CIN of the Registrar and Transfer Agent Pre-fill Name of the Registrar and Transfer Agent Registered office address of the Registrar and Transfer Agents (vii) *Financial year From date 01/04/2020 (DD/MM/YYYY) To date 31/03/2021 (DD/MM/YYYY) (viii) *Whether Annual general meeting (AGM) held Yes No (a) If yes, date of AGM 27/07/2021 (b) Due date of AGM 30/09/2021 (c) Whether any extension for AGM granted Yes No II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY *Number of business activities 1 S.No Main Description of Main Activity group Business Description of Business Activity % of turnover Activity Activity of the group code Code company C C6 III.
    [Show full text]
  • In the United States District Court for the District of New Jersey
    Case 1:19-md-02875-RBK-JS Document 121 Filed 06/17/19 Page 1 of 130 PageID: 1141 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY IN RE: VALSARTAN PRODUCTS LIABILITY LITIGATION No. 1:19-md-2875-RBK Hon. Robert Kugler Hon. Joel Schneider Jury Trial Demanded Consolidated Amended Class Action Complaint CONSOLIDATED AMENDED ECONOMIC LOSS CLASS ACTION COMPLAINT 1. COME NOW, the Consumer and Third Party Payor (“TPP”) Plaintiffs (collectively the “Class Plaintiffs”), who file this Consolidated Amended Economic Loss Class Action Complaint (“Master Class Complaint”)1 against the below-enumerated Defendants. I. INTRODUCTION 2. This case arises from adulterated, misbranded, and unapproved valsartan- containing drugs (“VCDs”) that were designed, manufactured, marketed, distributed, packaged, and sold by Defendants (identified and defined infra at Part II.C-H) in the United States, and which have been and remain the subject of one of the largest ongoing contaminated drug recalls ever in the United States. These VCDs are non-merchantable, and are not of the quality represented by Defendants named herein. 3. Valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the registered listed drugs (“RLDs”) Diovan® (“DIOVAN”) and Diovan HCT® (“DIOVAN HCT”), respectively. Amlodipine-valsartan and its combination therapy with hydrochlorothiazide are the generic versions of the RLDs of Exforge® (“EXFORGE”) and 1 This is one of three master complaints being filed in this multi-district litigation. The filing of three master complaints is to streamline the pleadings and issues for the parties’ mutual convenience only. Consumer Class Plaintiffs do not waive any claims that are not raised herein, or that are asserted in another master complaint.
    [Show full text]
  • Report on Final Campus Placement for Torrent Power. Ltd. on 16Th March, 2018 at S
    Report on Final Campus Placement for Torrent Power. Ltd. on 16th March, 2018 at S. R. Luthra Institute of Management, Surat Quick Details Torrent Power Ltd. Employer Date of Interview 16th March, 2018 Designation Offered Junior Executive Trainee Maximum Earning Potential INR 2,70,000 p.a. Interview conducted by Mrs. Vaishali Maisuria, Mrs. Parshi Min 60 No. of students Appeared No. of Students Selected 6 Company Overview Torrent Power is one of the leading brands in the Indian power sector, promoted by the Rs. 13116 crore Torrent Group – a group committed to its mission of transforming life by serving two of the most critical needs - healthcare and power. Torrent Pharmaceuticals Ltd., the flagship company of the Torrent Group, is a major player in the Indian pharmaceuticals industry with a vision of becoming a global entity in the arena. With an all-round experience in generation, transmission and distribution of power, and a proven track record of implementing large power projects, Torrent Power is the most experienced private sector player in Gujarat. Torrent has a generation capacity of 3202 MW and distributes power to 2.87 million customers annually in Ahmedabad, Gandhinagar, Surat, Bhiwandi and Agra. Company having world class power generation establishment at Ahmedabad, Surat (SUGEN- near Kamrej), Dahej (DGEN Dahej SEZ) and at Jamnagar (Wind power). Distribution Franchise business is one area which Torrent Power has been aggressively pursuing as part of its expansion plans. Torrent Power created history by entering into the country’s first distribution franchisee agreement with Maharashtra State Electricity Distribution Company Limited for Bhiwandi Circle in December 2006.
    [Show full text]
  • Company Reliance Industries Limited Tata Consultancy Services
    Top 1000 Private Sector Companies (Rank-wise List) Company Reliance Industries Limited Tata Consultancy Services (TCS) Infosys Technologies Ltd Wipro Limited Bharti Tele-Ventures Limited ITC Limited Hindustan Lever Limited ICICI Bank Limited Housing Development Finance Corp. Ltd. TATA Steel Limited Ranbaxy Laboratories Limited HDFC Bank Ltd Tata Motors Limited Larsen & Toubro Limited (L&T) Satyam Computer Services Ltd. Maruti Udyog Limited Bajaj Auto Ltd. HCL Technologies Ltd. Hero Honda Motors Limited Hindalco Industries Ltd Reliance Energy Limited Grasim Industries Limited Jet Airways (India) Ltd. Sun Pharmaceuticals Industries Ltd Cipla Ltd. Gujarat Ambuja Cements Ltd. Videsh Sanchar Nigam Limited The Tata Power Company Limited Sterlite Industries (India) Ltd. Associated Cement Companies Ltd. Nestlé India Ltd. Hindustan Zinc Limited GlaxoSmithKline Pharmaceuticals Limited Siemens India Ltd. Motor Industries Company Limited Mahindra & Mahindra Limited UTI Bank Ltd. Zee Telefilms Limited Bharat Forge Limited ABB Limited i-Flex Solutions Ltd. Dr. Reddy's Laboratories Ltd. Nicholas Piramal India Limited Kotak Mahindra Bank Limited Reliance Capital Ltd. Ultra Tech Cement Ltd. Patni Computer Systems Ltd. Wockhardt Limited Indian Petrochemicals Corporation Limited Biocon India Limited Essar Oil Limited. Asian Paints Ltd. Dabur India Limited Jaiprakash Associates Limited JSW Steel Limited Tata Chemicals Limited Tata Tea Limited Tata Teleservices (Maharashtra) Limited The Indian Hotels Co. Ltd. Glenmark Pharmaceuticals Limited NIRMA Limited Jindal Steel & Power Ltd HCL Infosystems Ltd. Cadila Healthcare Limited Colgate-Palmolive (India) Limited The Great Eastern Shipping Company Limited Aventis Pharma India Ltd Ashok Leyland Limited Pantaloon Retail (India) Limited Indian Rayon And Industries Limited Financial Technologies (India) Ltd United Phosphorus Limited Matrix Laboratories Limited Sesa Goa Limited Lupin Ltd Cummins India Limited Crompton Greaves Limited.
    [Show full text]
  • IST-2000-25187 TORRENT Requirements for Service Providers, Network Operators, Manufacturers
    Deliverable D1.2 IST-2000-25187 TORRENT Requirements for Service Providers, Network Operators, Manufacturers Project Number: IST-2000-25187 Project Title: TORRENT Deliverable Security*: PU CEC Deliverable Number: D1.2 Contractual Date of Delivery to the CEC: 31.7.2001 Actual Date of Delivery to the CEC: 18.9.2001 Title of Deliverable: Requirements for Service Providers, Network Operators, Manufacturers Work package contributing to the Deliverable: WP1 Type of Deliverable**: R Editor: Martin Potts Contributors: R. Phillips (Genuity), R. Tolstra (Tesion), E. Scharf, J. Griffiths, P. Hamer (QMUL), I. Borges, P. Rolo (PTIN), V. Apostolopoulou (OTEC), B. Martinez (Versaware), J. Rossebo, T. Olsen, H. Skaug, T. Konstali, T. Opperud, B. Haram (Telenor) * Security: PU – Public, PP - Restricted to other programme participants (including the Commission Services) RE - Restricted to a group specified by the consortium (including the Commission Services) CO - Confidential, only for members of the consortium (including the Commission Services) ** Type: R - Report, P - Prototype, D - Demonstrator, O - Other Abstract: The requirement for service providers, network operators and manufacturers is essentially to satisfy the user requirements as well as possible, in a fast and flexible manner, and for the least cost. The user requirements were identified in D1.1: “User Requirements”, as being that: all of the required services should be accessible, with the limitation that the quality may be affected according to the capabilities of the access network and the terminal. Such presentation adaptation should be automated for the user (ie. the user need not be aware of the underlying network). When a choice of access and/or core network technologies are available, the most suitable one will be (dynamically) chosen according to the user's instantaneous requirement for best quality, fastest response time, or lowest price (based on the current network conditions).
    [Show full text]
  • A. Contracts Or Arrangements with Any Related Party Under Section 188 Or in Which Any Director Is Concerned Or Interested Under Sub-Section (2) of Section 184
    FORM MBP-4 Register of contracts with related party and Bodies etc. in which directors are interested for the quarter ended June 30, 2020 [Pursuant to section 189 (1) and rule 16 (1)] A. Contracts or arrangements with any related party under section 188 or in which any director is concerned or interested under sub-section (2) of section 184 Sr. Date of Name of the Name of the Relation with Principal Whether the Date of Details of voting on such resolution Date of the Reference of Amount of Date of Signature Remarks, if No. Contract/ party with interested director director/ terms and transaction is approval at next meeting specific items contract or shareholders any Arrangement which company/ conditions at arm’s the meeting at which (a) to (g) arrangement ’ approval if contract is Nature of length basis of the Board register was under sub- (Rs. in crore) any entered into concern or placed for section (1) of interest signature section 188 No. of Directors Director Director Directors voting in s voting s present in favour against remainin the meeting g neutral 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 TORRENT PHARMACEUTICALS LIMITED B74 Between Torrent Sudhir Mehta Subsidiary Sale of Yes NA NA NA NA NA 06.08.2020 Rendering NA Exempted Apr, 20 to Pharmace- Samir Mehta of Holding Electricity of service under Jun 20 uticals Jinal Mehta Company 4.52 proviso 4 Limited to section 188(1) 120 Sr. No. Date of Name of the Name of the Relation with Principal terms Whether the Date of Details of voting on such resolution Date of the Reference of Amount of Date of Signature Remarks, if Contract/ party with interested director/ and conditions transaction is approval at next meeting specific items contract or shareholders any Arrangement which director company/ at arm’s the meeting at which (a) to (g) arrangement ’ approval if contract is Nature of length basis of the Board register was under sub- (Rs.
    [Show full text]
  • TORRENT-PO-2016-2017.Pdf
    INDEX Corporate Information ........................................................................................................................................................ 2 Notice ................................................................................................................................................................................ 3 Board’s Report ................................................................................................................................................................. 12 Management Discussion and Analysis ............................................................................................................................ 49 Business Responsibility Report ....................................................................................................................................... 58 Report on Corporate Governance ................................................................................................................................... 68 Independent Auditors’ Report on Standalone Financial Statements ................................................................................ 85 Standalone Financial Statements .................................................................................................................................... 92 Independent Auditors’ Report on Consolidated Financial Statements ........................................................................... 162 Consolidated Financial Statements ..............................................................................................................................
    [Show full text]
  • (15) Sr No Student Name Program Graduated
    5.2.2 Average percentage of placement of outgoing students during the last five years (15) Package in Download Sr No Student Name Program graduated from Name of Employer Lac. Proof Water and Sanitation management 1 Patel Devanshi Dharmendrabhai M. Sc. (Microbiology) 204000 Click Here Organisation 2 Vadera Jatin Arvindbhai M. Pharm (Regulatory Affairs) Urja Consumer health care (Velocity) 300000 Click Here 3 Divyanshu Joshi B.B.A., LL.B. (Hons.) Self Employed 470000 Click Here 4 Priyanshi Nagarkoti B.A., LL.B. (Hons.) Self Employed 470000 Click Here 5 Harsh Rathi B.B.A., LL.B. (Hons.) Self Employed 470000 Click Here 6 Jitendra Sharda B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 7 Harshit Chordia B.A., LL.B. (Hons.) Self Employed 470000 Click Here 8 Aditi Singh B.A., LL.B. (Hons.) Chir Amrit 470000 Click Here 9 Shubham Kejriwal B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 10 Shah Vyom Himanshu B. Com., LL.B. (Hons.) Adv. Gautam Joshi 470000 Click Here 11 Shreyans Ranka B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 12 Sarthak Sonwalkar B.A., LL.B. (Hons.) PRS LAMP Fellowship 470000 Click Here 13 Pranav Malhotra B. Com., LL.B. (Hons.) Self Employed 470000 Click Here 14 Prabhansh Sharma B.A., LL.B. (Hons.) Self Employed 470000 Click Here 15 Tanna Raj Sanjay B. Com., LL.B. (Hons.) H L Patel Advocates 470000 Click Here 16 Saransh Sharma B.A., LL.B. (Hons.) Uttar Pradesh Judiciary 470000 Click Here 17 Kunjal Arora B. Com., LL.B.
    [Show full text]
  • 1 in the United States District Court for the District Of
    Case 1:19-cv-09348-RBK-JS Document 1 Filed 04/05/19 Page 1 of 48 PageID: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY CAMDEN VICINAGE PAULETTE SILBERMAN, Individually and on behalf of all others similarly situated, Civil Action No.:______________ Plaintiff, Jury Trial Demanded v. Complaint-Class Action ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.; HUAHAI US INC.; PRINSTON PHARMACEUTICAL INC. d/b/a SOLCO HEALTHCARE LLC; SOLCO HEALTHCARE U.S., LLC; TEVA PHARMACEUTICAL INDUSTRIES LTD.; ACTAVIS LLC; TEVA PHARMACEUTICALS USA, INC.; CARDINAL HEALTH, INC.; THE HARVARD DRUG GROUP, L.L.C.; MAJOR PHARMACEUTICALS, INC.; ARROW PHARM (MALTA) LTD.; ACTAVIS PHARMA, INC.; TORRENT PRIVATE LIMITED; TORRENT PHARMACEUTICALS, LTD.; TORRENT PHARMA, INC.; AUROBINDO PHARMA, LIMITED; AUROBINDO PHARMA USA, INC.; AUROLIFE PHARMA LLC; AND JOHN DOES 1-100, Defendants. 1. Plaintiff Paulette Silberman (“Plaintiff”), individually and on behalf of all others similarly situated, brings this action against Zhejiang Huahai Pharmaceuticals Co., Ltd. (“ZHP”), Huahai US Inc. (“Huahai US”), Prinston Pharmaceutical Inc. d/b/a Solco Healthcare LLC (“Prinston"), Solco Healthcare U.S., LLC (“Solco”), Teva Pharmaceutical Industries Ltd. (“Teva”), Actavis LLC (“Actavis”), Teva Pharmaceuticals USA, Inc. (“Teva USA”), Cardinal Health, Inc. (“Cardinal”), The Harvard Drug Group, L.L.C. (“Harvard”), Major Pharmaceuticals, Inc. (“Major”), Arrow Pharm (Malta) Ltd. (“Arrow”), Actavis Pharma, Inc. (“Actavis Pharma”), 1 Case 1:19-cv-09348-RBK-JS Document 1 Filed 04/05/19 Page 2 of 48 PageID: 2 Torrent Private Limited (“Torrent Private”), Torrent Pharmaceuticals, Ltd. (“Torrent Pharmaceuticals”), Torrent Pharma, Inc. (“Torrent Pharma”) (ZHP, Huahai US, Prinston, Solco, Teva, Actavis, Teva USA, Cardinal, Harvard, Major, Arrow, Actavis Pharma, Torrent Private, Torrent Pharmaceuticals, and Torrent Pharma, collectively, “ZHP Defendants”), Aurobindo Pharma, Limited (“Aurobindo”), Aurobindo Pharma USA, Inc.
    [Show full text]
  • Press Release- Torrent }>Harm a Acquires Bio-Pharm Inc
    ~"iorrenr ~ PHRRmR !81h .January, 2018 ~ Dy. General Manager (Listing Dept.) The Manager·- Listin ept., BSE Lnntted., National Stock Ex ange of India Ltd., Corporate Relationship Dept., Exchange Pia- , 51h Floor, I st Floor, New Trading Ring, Plot No.. , G. Block, P . .1. Towers, Dalal Street, Fort, Band· - Kurla Complex, Bandra (E), Mumbai- 400 00 I mbai -- 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Press Release- Torrent }>harm a acquires Bio-Pharm Inc. We would like to inform you that Torrent Pharmaceuticals Limited, through its wholly owned subsidiary Torrent Pharma Inc., has acquired Bio-Pharm Inc., a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA. A press release with respect to the above matter is enclosed herewith for your information and records. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY Encl: As above TORRENT PHARMACEUTICALS LIMITED C!N: L24230GJ1972PLC002126 Reg.Office: Torrent House, Off Ashram Road, Ahmedabad. 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, www.torrentpharma.com Torrent Pharma acquires Bio-Phann, Inc. Ahmedabad, 18'" .January, 2018: Torrent Pharmaceuticals Limited ("Torrent") today, announced the acquisition of Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA. · Established in 1992, BPI has a proven track record in the research & development and manufacturing of oral solutions, suspensions and suppositories. Its 75,000 sq. ft US FDA registered facility has manufacturing capabilities for controlled substances which can be manufactured in US only as per Government guidelines (DEA Schedule 11-V). To date, BPI has 10 approved AND As, 10 AND As under review at the FDA for itself and it's partners and has an additional 17 products under development.
    [Show full text]